DEF: Cocrystal Pharma Sets 2026 Annual Meeting Date

Cocrystal Pharma, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on July 14, 2026, to elect directors, ratify auditors, and address potential meeting adjournments.

Summary

• Cocrystal Pharma, Inc. is holding its 2026 Annual Meeting of Stockholders on July 14, 2026, at 11:00 a.m. Eastern Time.
• The meeting will be conducted virtually via audio conference call, with no in-person attendance option.
• Key agenda items include the election of five directors for one-year terms, ratification of Weinberg & Company as the independent registered public accounting firm for the year ending December 31, 2026, and approval to adjourn the meeting if necessary.
• The record date for determining stockholders entitled to vote is May 19, 2026.
• Proxy materials are being furnished electronically via the internet, with a notice of availability mailed on or about May 29, 2026.
• A total of 13,787,453 shares of common stock were outstanding and entitled to vote as of the record date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily concerns procedural matters for the annual meeting and corporate governance, rather than significant financial performance updates or strategic shifts.

Positives

• The company is holding its annual meeting to ensure corporate governance and provide stockholders with voting opportunities.
• The virtual format enhances accessibility for stockholders regardless of geographic location.
• The company is providing clear instructions for accessing proxy materials and voting, including options for internet, email, mail, fax, and during the meeting.
• The Board of Directors is recommending a vote FOR all proposals, indicating confidence in the nominees and the proposed auditor.
• The company has a robust Code of Ethics and Insider Trading Policy in place.

Negatives

• The company has experienced significant net losses in recent years, with a net loss of $8,831,000 in 2025 and $17,504,000 in 2024.
• Executive compensation is not directly tied to total shareholder return or operating performance, as the company is in a pre-revenue drug discovery phase.
• The company's compensation policies are not believed to encourage excessive risk-taking, but the primary risks are related to R&D activities.

Risks

• The primary risks for Cocrystal Pharma, beyond liquidity, relate to the results of its research and development activities.
• The company is subject to SEC regulations and potential future regulatory actions, as evidenced by the past SEC complaint against Dr. Phillip Frost.
• The company's ability to continue as a going concern is dependent on its ability to secure future financing and achieve profitability.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it outlines the company's upcoming annual meeting agenda, which includes the election of directors and ratification of auditors, and implies ongoing operations and governance activities.

Management Comments

• The Board believes that the separation of the Chairman and CEO roles provides sufficient Board oversight and management autonomy.
• Management does not believe that the Company maintains compensation policies or practices that are reasonably likely to have a material adverse effect on the Company.
• As a drug discovery company developing product candidates without revenue from product sales, net losses have not been a factor in determining compensation; instead, the focus is on meeting goals that can lead to substantial shareholder returns.

Industry Context

StockSavvy.ai notes that this filing is a standard proxy statement for a publicly traded company, outlining governance and shareholder voting matters. For a biopharmaceutical company like Cocrystal Pharma, such filings are crucial for transparency regarding board composition, executive compensation, and auditor selection, all of which are key considerations for investors in this highly regulated and R&D-intensive sector.

Corporate Governance

Legal Proceedings

• On September 7, 2018, the SEC filed a complaint against Dr. Philip Frost, a director and principal stockholder, a trust he controls, and OPKO Health, Inc., among others. Final judgments were entered on January 10, 2019, by consent, permanently enjoining Dr. Frost from violating certain anti-fraud provisions of the Securities Act of 1933, future violations of Section 13(d) of the Exchange Act, and participating in penny stock offerings with certain exceptions.

Related Party Transactions

• The Company entered into a three-year lease extension on August 14, 2024, with a limited liability company controlled by Dr. Phillip Frost, a director and principal stockholder. Rent and other expenses paid for the years ended December 31, 2025 and 2024 were $62,000 and $63,000, respectively.
• On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors, including Frost Gamma Investments Trust (in which Dr. Phillip Frost is trustee), for the purchase of shares at $1.97 per share. Fred Hassan, who later became a director, was the second purchaser.

Stakeholder Impact

• Shareholders: The meeting provides an opportunity for shareholders to vote on director elections and auditor ratification, influencing corporate governance. Executive compensation details are also disclosed, impacting shareholder value perception.
• Management and Employees: Executive compensation is detailed, and policies like the Code of Ethics and Insider Trading Policy govern their conduct.
• Auditors: The ratification of Weinberg & Company as the independent registered public accounting firm is a key agenda item.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on July 14, 2026.
• Elect five directors for a one-year term.
• Ratify the selection of Weinberg & Company as the independent registered public accounting firm for the year ending December 31, 2026.
• Potentially adjourn the Annual Meeting if necessary to solicit further proxies.
• File a Current Report on Form 8-K within four business days after the Annual Meeting to announce voting results.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic shifts that would warrant a buy or sell recommendation. The company continues to operate in a pre-revenue, R&D-intensive phase with significant net losses. Therefore, a 'hold' recommendation is appropriate, pending future developments in its drug pipeline and financing.

Keywords

Cocrystal Pharma, DEF 14A, Proxy Statement, Annual Meeting, Stockholders Meeting, Director Election, Independent Auditor, Corporate Governance, Executive Compensation, SEC Filing